Corrected summary: SAR-bisPSMA, an Australian-developed radiopharmaceutical, shows superior lesion detection, higher tumour uptake, and greater clinical impact than current PSMA PET agents. Supported by strong evidence, it offers flexible imaging, a favourable safety profile, and targets a multi-billion dollar prostate cancer diagnostics and therapy market.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.